= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Madunic

MSACL 2018 EU Abstract

Topic: Glycomics

Podium Presentation in the Ether on Wednesday at 11:20 (Chair: Guinevere Lageveen-Kammeijer)

In Depth O-Glycosylation Structural Analysis of Colorectal Cancer Cell Lines

Katarina Madunic (Presenter)
Leiden University Medical Center

Presenter Bio(s): Katarina Madunic received her diploma in 2012. from Faculty of Pharmacy and Biochemistry, University of Zagreb, Croatia. She fell in love with glycans while working on master thesis project about high throughput HILIC analysis of fluorescently labelled N-glycans in Genos Ltd. Croatia. In August 2016. she started her PhD project at Leiden University Medical Centre under supervision of Prof.Dr. Manfred Wuhrer focusing on exploring the glycosylation of colorectal cancer within GlycoCan consortium.

Authors: Katarina Madunic1, Stephanie Holst-Bernal1, Kathrin Stavenhagen1,3, Chunsheng Jin2, Niclas Karlsson2, Manfred Wuhrer1
1 Leiden University Medical Center, Center for Proteomics and Metabolomics, Leiden, The Netherlands 2 Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg 3 Beth Israel Deaconess Medical Center - Harvard Medical School, Boston

Abstract

Altered glycosylation has been widely described in cancer. However, little is known about O- glycosylation due to the complexity of the analytical approaches. Many studies used single cell lines to investigate glycosylation changes in cancer without taking into account the differences between cell lines. During this study O-glycosylation signatures of 25 colorectal cancer cell lines were examined by nano-PGC-LC-ESI-MS, allowing the differentiation between isomeric structures and their association with different cell phenotypes. Our results have shown profound differences between O-glycomes of the cell lines revealing that single cell line studies may not provide representative results.


Financial Disclosure

DescriptionY/NSource
GrantsyesLUMC- GlycoCan Marie Curie grant
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no